FINWIRES · TerminalLIVE
FINWIRES

POET Technologies Teams Up With Lumilens for Wafer-Level Photonic Integration Project

By

POET Technologies (POET) and Lumilens said Thursday they have signed a supply agreement for a partnership to develop a new class of wafer-level photonic integration for artificial intelligence infrastructure.

Lumilens has placed an initial purchase order with POET for Electrical-Optical Interposer-based engines valued at $50 million, the companies said, adding that orders may increase to more than $500 million over five years.

POET has granted Lumilens a warrant to buy up to about 22.9 million shares, exercisable over nine years at $8.25 per share, the companies said.

The warrant is immediately exercisable for nearly 2.3 million shares, with the rest of the shares vesting and becoming exercisable in tranches linked to payments by Lumilens for purchase orders totaling up to $500 million, according to the companies.

POET shares were up more than 33% in Thursday trading.

Price: $19.13, Change: $+4.76, Percent Change: +33.09%

Related Articles

Australia

Contango Q1 Net Loss Narrows

Contango Silver and Gold (CTGO) shares were down more than 3% in Thursday trading after the company missed Q1 earnings expectations.The company reported a Q1 net loss Thursday of $0.83 per diluted share, narrowing from a loss of $1.88 a year earlier.Three analysts surveyed by FactSet expected earnings of $0.65.Price: $25.52, Change: $-0.84, Percent Change: -3.19%

$CTGO
Australia

Market Chatter: OpenAI Preparing for Possible Legal Action Against Apple

Microsoft-backed (MSFT) OpenAI is preparing possible legal action against Apple (AAPL) as the partnership between the two companies has become strained, Bloomberg reported Thursday, citing people familiar with the matter.OpenAI's lawyers are working with an outside law firm on a range of options, including sending Apple a notice alleging breach of contract without actually filing a full lawsuit at the outset, the report said, citing the people.OpenAI and Apple didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $297.73, Change: $-1.14, Percent Change: -0.38%

$AAPL$MSFT
Australia

Oppenheimer Raises Biogen Price Target to $300 From $275, Maintains Outperform Rating

Biogen (BIIB) has an average rating of overweight and mean price target of $0, according to analysts polled by FactSet.Price: $194.50, Change: $-10.03, Percent Change: -4.90%

$BIIB